Edgestream Partners L.P. Purchases 135,891 Shares of Immunome, Inc. $IMNM

Edgestream Partners L.P. purchased a new position in Immunome, Inc. (NASDAQ:IMNM – Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 135,891 shares of the company’s stock, valued at approximately $2,923,000. Edgestream Partners L.P. owned about 0.12% of Immunome as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in Immunome during the 2nd quarter worth about $186,588,000. Wellington Management Group LLP raised its stake in Immunome by 10.1% in the 2nd quarter. Wellington Management Group LLP now owns 5,210,216 shares of the company’s stock valued at $110,404,000 after purchasing an additional 478,239 shares during the last quarter. Primecap Management Co. CA acquired a new position in Immunome in the 2nd quarter valued at about $97,081,000. Readystate Asset Management LP raised its stake in Immunome by 23.3% in the 2nd quarter. Readystate Asset Management LP now owns 1,605,820 shares of the company’s stock valued at $34,027,000 after purchasing an additional 303,958 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in Immunome by 285.6% in the 1st quarter. Bank of America Corp DE now owns 781,607 shares of the company’s stock valued at $17,094,000 after purchasing an additional 578,890 shares in the last quarter. 44.58% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on IMNM shares. William Blair started coverage on shares of Immunome in a research note on Friday, October 16th. They set an “outperform” rating on the stock. HC Wainwright reissued a “buy” rating on shares of Immunome in a research report on Tuesday, October 27th. Piper Sandler reduced their price objective on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 10th. Alliance Global Partners started coverage on shares of Immunome in a research report on Monday, September 21st. They set a “buy” rating and a $32.00 target price on the stock. Finally, Truist Financial raised their target price on shares of Immunome from $37.00 to $38.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Fourteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $33.85.

Read Our Latest Stock Analysis on Immunome

Immunome Trading Down 5.7%

Shares of NASDAQ:IMNM opened at $15.67 on Friday. The firm has a market cap of $1.85 billion, a price-to-earnings ratio of -5.94 and a beta of 2.68. The stock’s 50-day moving average price is $19.74 and its two-hundred day moving average price is $22.01. Immunome, Inc. has a 12-month low of $15.55 and a 12-month high of $30.06.

Immunome (NASDAQ:IMNM – Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.14). As a group, research analysts forecast that Immunome, Inc. will post -2.64 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Immunome news, insider Jack Higgins sold 13,200 shares of the stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $25.32, for a total transaction of $334,224.00. Following the transaction, the insider owned 65,050 shares of the company’s stock, valued at $1,647,066. This trade represents a 16.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 7.21% of the company’s stock.

Immunome Profile

(Free Report)

Immunome is a biotechnology company focused on discovering and developing therapies for cancer. It uses an antibody-discovery platform to identify targets and develop medicines intended to address areas of significant unmet medical need. The company’s research and development programs include targeted cancer treatments, such as antibody-based therapies and other drug candidates. Its portfolio has included investigational medicines for solid tumors and other cancers; these products are in development and are not necessarily approved for commercial use.

Read More

Want to see what other hedge funds are holding IMNM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunome, Inc. (NASDAQ:IMNM – Free Report).

Institutional Ownership by Quarter for Immunome (NASDAQ:IMNM)

Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.